⚡️ NIMITZ HEALTH NEWS FLASH ⚡️ 

“Health Subcommittee: The Fiscal Year 2027 Department of Health and Human Services Budget”

House Energy & Commerce Health Subcommittee

April 21st, 2026 (recording linked here)

WITNESS

• The Honorable Robert F. Kennedy, Jr.: Secretary, U.S. Department of Health and Human Services

QUICK SUMMARY

• The hearing focused on the FY2027 HHS budget, emphasizing prevention, affordability, transparency, and efforts to address chronic disease and healthcare system inefficiencies.

• Significant debate centered on vaccination policy, public health trust, and the federal response to measles and other preventable diseases.

• Members raised concerns about proposed funding changes, including Medicaid, maternal health programs, NIH research, and public health infrastructure.

• Discussions highlighted healthcare cost drivers, including drug pricing, hospital consolidation, Medicare Advantage, and fraud, waste, and abuse in federal programs.

• Additional topics included rural healthcare investment, domestic pharmaceutical manufacturing, workforce shortages, and emerging areas like wearables, nutrition policy, and rare disease innovation.

🐘 Republicans

• Emphasized prevention, nutrition, transparency, and market-based reforms as key to lowering costs and improving long-term health outcomes.

• Highlighted efforts to combat fraud, expand rural healthcare investment, and accelerate drug development and domestic manufacturing.

• Defended administration policies on Medicaid, vaccines, and regulation as restoring accountability and challenging entrenched systems.

🫏 Democrats

• Criticized proposed funding cuts and policy changes as undermining access to care, public health programs, and scientific research.

• Raised concerns about vaccine policy, misinformation, and declining trust in public health institutions contributing to disease outbreaks.

• Argued that affordability and coverage were worsening due to higher premiums, reduced benefits, and administrative barriers.

MEMBER OPENING STATEMENTS

• Vice Chair Harshbarger (R-TN) opened the hearing by welcoming Secretary Kennedy and outlining the administration’s fiscal year 2027 health budget priorities. She emphasized challenges such as rising chronic disease, healthcare costs, and access issues, particularly in rural communities. She highlighted support for prevention, transparency, affordability, and program integrity, including efforts to reduce fraud and expand access to care. She concluded by expressing interest in strengthening rural health systems and ensuring access to innovative treatments.

• Ranking Member DeGette (D-CO) opened by arguing that the past 15 months had been damaging for public health and scientific research. She cited concerns about rising measles cases, reduced research funding, and what she described as the politicization of health agencies. She criticized Secretary Kennedy’s actions on vaccines, mRNA research, and public health programs, asserting they had undermined trust and harmed outcomes. She concluded that current leadership had weakened the nation’s health system and called for a return to evidence-based decision-making.

• Full Committee Chair Guthrie (R-KY) thanked Secretary Kennedy for appearing and focused on Republican efforts to address healthcare challenges such as drug abuse and fraud in federal programs. He highlighted recent hearings examining cost drivers and promoting healthier lifestyles, including nutrition initiatives. He commended the administration’s work on dietary guidelines and anti-fraud efforts, emphasizing their importance for protecting patients and preserving programs. He concluded by expressing support for continued collaboration to improve healthcare outcomes.

• Full Committee Ranking Member Pallone (D-NJ) argued that recent policies had destabilized the healthcare system, increasing costs and reducing access to care. He criticized major healthcare cuts, the loss of insurance coverage for millions, and reduced funding for Medicare and Medicaid. He also raised concerns about vaccine policy changes, misinformation, and halted research funding, which he said had undermined public health and innovation. He concluded by accusing Secretary Kennedy of failing to provide transparency and warned that the damage to the healthcare system could take decades to repair.

WITNESS OPENING STATEMENTS

• Secretary Kennedy opened by thanking the committee and framing the moment as a generational turning point driven by rising chronic disease and systemic failures in healthcare policy. He argued that the administration had begun reversing these trends through reforms focused on drug pricing, transparency, prevention, and reducing regulatory burdens. He highlighted initiatives including nutrition policy changes, anti-fraud efforts, expanded rural health investments, and increased access to medical data and treatments. He concluded by calling for continued collaboration with Congress to implement long-term reforms aimed at improving public health and lowering costs.

QUESTION AND ANSWER SUMMARY

• Vice Chair Harshbarger (R-TN) began questioning by asking the Secretary to clarify his approach to measles and vaccine policy. Secretary Kennedy responded that the measles outbreak predated his tenure, emphasized global trends, and argued that treatment and patient compassion should accompany vaccination efforts.

  Vice Chair Harshbarger also raised peptide access and compounding policy, and Secretary Kennedy agreed to work with her while noting recent regulatory changes to expand access and reduce black market activity.

• Ranking Member DeGette (D-CO) focused on maternal health programs and contraception access, questioning proposed eliminations of the CDC Safe Motherhood program and Title X family planning funding. Secretary Kennedy maintained that maternal health remained a priority and argued programs were being consolidated rather than eliminated.

  Ranking Member DeGette pressed for a commitment on contraception access, but Secretary Kennedy did not give a direct yes-or-no answer and instead emphasized broader maternal health initiatives.

• Full Committee Chair Guthrie (R-KY) asked about rural healthcare funding and Medicaid reforms, particularly the Rural Health Transformation Fund. Secretary Kennedy described increased funding for rural hospitals, workforce investments, and expanded telehealth and infrastructure support. Rep. Guthrie also questioned fraud in federal programs and global competition with China, and Secretary Kennedy highlighted enforcement actions, program integrity reforms, and efforts to accelerate drug approvals and maintain U.S. competitiveness.

• Full Committee Ranking Member Pallone (D-NJ) focused on healthcare costs, coverage losses, and potential links between healthcare cuts and military spending. Secretary Kennedy denied that Medicaid was being cut and pointed to increased spending levels. Rep. Pallone criticized administration priorities and argued that healthcare affordability and coverage were being undermined, while Secretary Kennedy did not directly commit to opposing future cuts tied to other spending.

• Rep. Bilirakis (R-FL) asked about rare disease policy, newborn screening, and environmental links to neurodegenerative diseases. Secretary Kennedy highlighted expanded screening panels, accelerated approval pathways for rare disease treatments, and increased research into environmental toxins. He emphasized a shift toward studying links between environmental exposure and chronic disease.

• Rep. Ruiz (D-CA) questioned the nomination process for the CDC director and raised concerns about vaccine policy and agency leadership. Secretary Kennedy stated his staff had recommended the nominee and defended his actions on vaccines, denying allegations of dismantling programs.

  Rep. Ruiz criticized his record and public statements, arguing they undermined vaccination efforts and public health trust.

• Rep. Carter (R-GA) allowed Secretary Kennedy to respond to prior criticisms, particularly on vaccines. Secretary Kennedy reiterated that he was not anti-vaccine and emphasized increased funding for vaccine research while calling for stronger safety testing standards.

  Rep. Carter then shifted to 340B drug pricing reform and domestic manufacturing. Secretary Kennedy agreed the program had expanded beyond its original intent and supported working with Congress on reforms, while also highlighting efforts to reshore pharmaceutical manufacturing and strengthen supply chains.

• Rep. Dingell (D-MI) raised concerns about declining vaccination rates, measles resurgence, and public health funding cuts. Secretary Kennedy attributed declining vaccination rates to broader global trends and COVID-era distrust rather than his policies.

  Rep. Dingell also questioned nursing home staffing rule changes, and Secretary Kennedy argued the prior rule would have forced closures, especially in rural areas.

• Rep. Joyce (R-PA) focused on fraud prevention, nutrition education, and hospital consolidation. Secretary Kennedy highlighted efforts to shift to real-time fraud detection, expand nutrition training in medical education, and address payment disparities through policy changes. He also agreed to review the enforcement of physician compensation standards and reimbursement concerns.

• Rep. Kelly (D-IL) questioned Medicaid funding levels, maternal health program cuts, and hospital closures. Secretary Kennedy denied Medicaid cuts, framing changes as increased spending and program consolidation. Rep. Kelly argued these policies were harming vulnerable populations and raised concerns about SNAP cuts and access to nutritious food.

• Rep. Balderson (R-OH) asked about prevention strategies, wearable technology, Alzheimer’s detection, and workforce shortages. Secretary Kennedy emphasized the role of wearable devices in behavior change, early detection, and integration with health data systems. He also highlighted workforce investments, rural training programs, and expanded funding for community health centers.

• Rep. Barragán (D-CA) raised concerns about access to glucose monitors under Medicare and Medicaid, contraception access, and Alzheimer’s research funding cuts. Secretary Kennedy expressed willingness to address preventive care gaps but declined to discuss Title X due to litigation. He maintained that Alzheimer’s research remained a priority despite proposed funding reductions.

• Rep. Miller-Meeks (R-IA) focused on contraception access, fraud prevention legislation, nutrition policy, and rural healthcare funding flexibility. Secretary Kennedy expressed support for over-the-counter contraception, anti-fraud legislation, and expanded nutrition education. He also committed to follow up on rural workforce funding flexibility questions.

• Rep. Schrier (D-WA) questioned changes to hepatitis B vaccination guidance and raised concerns about broader vaccine skepticism affecting public health behaviors. Secretary Kennedy defended his position, emphasizing choice and denying discouragement of vaccines. Rep. Schrier argued that messaging was undermining trust and could lead to increased disease risk and poorer outcomes.

• Rep. Cammack (R-FL) emphasized prevention, nutrition, and healthcare system incentives. Secretary Kennedy discussed shifting from fee-for-service to outcome-based care and aligning incentives toward health outcomes. He also highlighted use of AI to accelerate FDA review processes.

• Rep. Trahan (D-MA) questioned ACA coverage losses, rising premiums, and Medicaid policy impacts. Secretary Kennedy attributed coverage losses to fraud and eligibility enforcement, while Rep. Trahan argued administrative barriers and affordability were reducing coverage and increasing system strain.

• Rep. James (R-MI) focused on price transparency enforcement and Lyme disease diagnosis. Secretary Kennedy described new transparency regulations and enforcement actions, as well as increased research and awareness efforts for Lyme disease and long COVID.

• Rep. Veasey (D-TX) sharply criticized Secretary Kennedy’s vaccine record and messaging, linking it to measles outbreaks. Secretary Kennedy denied being anti-vaccine and rejected claims that he had changed his position due to political pressure.

• Rep. Bentz (R-OR) discussed market-based healthcare reforms, price transparency, and insurance competition. Secretary Kennedy supported market mechanisms to reduce costs and outlined multiple initiatives aimed at lowering prices, including drug pricing reforms and reducing fraud.

• Rep. Fletcher (D-TX) raised concerns about NIH funding cuts and U.S. competitiveness in biomedical research. Secretary Kennedy acknowledged concerns but stated budget constraints required reductions while maintaining overall leadership in research funding.

• Rep. Rulli (R-OH) asked about FDA classification of a thyroid drug and broader regulatory issues. Secretary Kennedy acknowledged internal disagreement and offered to work with Congress on resolving the issue. He also reiterated his stance on vaccine safety testing and openness to scientific debate.

• Rep. Ocasio-Cortez (D-NY) questioned Medicare Advantage overpayments and fraud by insurers. Secretary Kennedy agreed on concerns about upcoding and fraud but defended recent payment increases as necessary to maintain patient access and market stability.

• Rep. Houchin (R-IN) focused on domestic pharmaceutical manufacturing and long COVID research. Secretary Kennedy highlighted efforts to reshore supply chains, streamline FDA approvals, and expand research into long COVID diagnostics and treatment.

• Rep. Auchincloss (D-MA) raised concerns about political interference in FDA decision-making and cited whistleblower claims. Secretary Kennedy denied these allegations and stated decisions were based on career scientists. Rep. Auchincloss argued that recent actions demonstrated political influence over scientific processes.

• Rep. Langworthy (R-NY) asked about healthcare price transparency and biosimilars. Secretary Kennedy described enforcement actions, penalties for noncompliance, and efforts to accelerate biosimilar approvals to increase competition and reduce costs.

• Rep. Carter (D-LA) questioned canceled SAMHSA grants and substance use funding. Secretary Kennedy acknowledged the cancellations were a mistake that was quickly reversed and attributed issues to internal processes. Rep. Carter criticized the disruption and raised concerns about broader funding changes affecting mental health services.

• Rep. Landsman (D-OH) raised concerns about delayed grant funding, Medicaid cuts, and Medicare Advantage policies. Secretary Kennedy denied Medicaid cuts and defended program changes, while Rep. Landsman argued that coverage losses and funding reductions were real and harmful.